Aurobindo Pharma has received a warning letter from the United States Food and Drug Administration (USFDA) relating to its unit XI, active pharmaceutical ingredient (API) manufacturing facility situated at Srikakulam, in the state of Andhra Pradesh. This action follows the earlier inspection of the site by the USFDA in February 2019.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
